Replies to post #118536 on Biotech Values

[ghmm]

I wasn't familiar with them but I did have this link bookmarked
http://www.amirapharm.com/pipeline.html
So they must have PR'd something some time ago. I am still looking for some nice way to play IPF (i.e. public, not a huge market cap and most importantly promising drug(s)). I must admit to not doing as a good of job the past few years in keeping track of the landscape.

It seems more and more speculative companies have PR'd something (most probably junk/long shots). An alert the other day bought up this trial
http://clinicaltrials.gov/ct2/show/NCT01335477
So there appears to be another Phase 3 candidate. They supplied InterMune with Actimmune and believe they had x-US rights as well.

[ghmm]

This IPF candidate now belongs to BMY

http://www.xconomy.com/san-diego/2011/07/21/bristol-myers-acquires-amira-pharmaceuticals-for-325-million-scoops-up-lung-drug/

Amira Pharmaceuticals, a privately held company in San Diego, has agreed to be acquired by New York-based Bristol-Myers Squibb (NYSE: BMY) for $325 million in cash upfront, plus additional milestone payments of $150 million, meaning the deal could be worth up to $475 million for Amira shareholders. Bristol said in a statement that it plans to retain Amira’s scientists, and keep them in San Diego. Amira had 25 employees at last count, in November.